Cencora, Inc. COR is well-poised for growth on the back of a robust U.S. Healthcare Solutions business and product launches.

TimesSquare Capital Management, an equity investment management company, released its “U.S. Focus Growth Strategy” second-quarter 2024 investor letter. A copy of the letter can be downloaded ...

TimesSquare Capital Management, an equity investment management company, released its “U.S. Focus Growth Strategy” first quarter 2025 investor letter. A copy of the letter can be downloaded here.

Final Takeaway Cencora delivered a strong quarter with notable growth in the U.S. Healthcare Solutions segment, driven by specialty products and strategic investments.

Cencora Inc (COR) reports a 13% revenue increase and raises full-year guidance, driven by robust US healthcare solutions and strategic market positioning.

A notable development in Cencora's growth strategy is its acquisition of RCA. This strategic move is anticipated to expand the company's specialty footprint in high-growth areas, potentially opening ...

Cencora, Inc. reported significant growth in its fiscal 2024 results, boasting a 14.7% increase in fourth-quarter revenue to $79.1 billion and a 12.1% rise for the year to $294.0 billion. Despite ...

Cencora’s international segment, however, faced challenges due to subdued clinical trial activity, prompting a slight adjustment in revenue growth expectations.

Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their ...

Scrutiny from the public and politicians over exorbitant branded and specialty drug list prices could result in lower price inflation long term, slowing Cencora's top-line growth.

Cencora, Inc. COR is well-poised for growth on the back of robust U.S. Healthcare Solutions business and product launches. However, intense competition is a concern. Shares of this Zacks Rank #3 ...